A randomized, phase IIa exploratory trial to assess the safety and preliminary efficacy of LEO 43204 in patients with actinic keratosis.


BACKGROUND LEO 43204 is a novel ingenol derivative in development for the treatment of actinic keratosis. OBJECTIVES To compare the safety and preliminary efficacy of three doses of LEO 43204 with ingenol mebutate in actinic keratoses (AKs). METHODS Patients with at least three visible, discrete, nonkeratotic AKs on four separate selected treatment… (More)
DOI: 10.1111/bjd.14245


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.